Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.

Rhea-AI Summary

Goldman Small Cap Research publishes research report on Regen BioPharma, Inc. (OTCPK:RGBP)

Positive

• Regen BioPharma may be poised to initiate a Phase I clinical trial in the large autoimmune therapeutic category
• Autoimmune therapeutic segment projected to grow from $71.5 billion in 2023 to $123.5 billion in 2033
• Regen BioPharma has a deep IP portfolio and diverse preclinical product pipeline
• Target price represents fair market cap for a preclinical firm with potential for price gains

Negative

• None.

BALTIMORE, MD / ACCESSWIRE / October 4, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Regen BioPharma, Inc. (OTCPK:RGBP). Leveraging its deep IP and surprising results from Phase I of in vitro experiments, Regen may be poised to initiate a Phase I clinical trial in the large autoimmune therapeutic category. The Goldman report carries a price target. To view the new research report, along with disclosures and disclaimers, or to download the report in its entirety, please visit: https://bit.ly/48BJkGG.

Publicly traded Regen BioPharma is focused on the immunology, oncology and immunotherapy spaces. The Company's approach is to rapidly advance novel, autologous cell therapies through pre-clinical and Phase I and Phase II clinical trials. Regen is also focused on small molecule therapies for treating cancer and autoimmune disorders. Historically, there has been a strong appetite for companies with a footprint in the cancer and autoimmune segments and Regen BioPharma is an emerging player in these arenas.

In the Opportunity Research report, analyst Rob Goldman reviews the autoimmune and cancer categories, along with a focus on a validated target within the Company's path to creating immune checkpoint medicines. Moreover, the report highlights Regen BioPharma's current positioning, and how development progress could dramatically change the Company's outlook.

Regen BioPharma May Not Be Underfollowed for Long

Goldman commented, "Regen BioPharma may be an underfollowed and undervalued preclinical player today, but major steps on the R&D front could serve as a near-term catalyst for its stock. A recent set of experiments led by a highly regarded CRO unearthed surprising results in a recent study which could lead to a series of game-changing future milestone events. Regen has now evolved from primarily a cancer therapy product approach to a firm that now features autoimmune therapy development as well."

Autoimmune Market is Huge; Chronic Nature Attracts Investor Attention

"The autoimmune therapeutic segment is massive and impacts millions of sufferers around the world," noted Goldman. "According to Future Market Insights, this segment is projected to grow from an estimated $71.5 billion in 2023 to $123.5 billion in 2033. Autoimmune disorders (ADs) are a family of more than 100 chronic, and often disabling, illnesses broadly characterized by immune system dysfunction leading to the loss of tolerance to self-antigens, presence of increased level of auto-antibodies, inflammatory and mediatory cells and resulting chronic inflammation. ADs affect up to 9% of the population and can represent considerable personal and public health burdens."

Inherent Competitive Advantages and History Versus its Peers

Goldman stated, "The Company has a deep IP portfolio centered around a key validated target and a diverse preclinical product pipeline, with a focus on immune-oncology and autoimmune diseases. Regen's next-gen technology platforms have led to multiple IND submissions and an IND approval. Upcoming milestones include new CRO confirmatory study results, animal studies, and an IND submission. The IND submission could lead to a Phase I clinical (human) trial in 18+ months."

Reasonable 6-12 Month Target Price, Future Upside Led by Milestones

"Our target price represents a market cap which we believe is fair and typical for a preclinical firm with deep IP, next-gen tech, multiple target therapy markets, and one with a potential product on a clinical trial path. We believe additional price gains can be achieved as new objectives are met in the coming quarters," Goldman concluded.

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.

Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published company report on Regen BioPharma, Inc. ("The Company"). The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Regen BioPharma, Inc. The information includes authorized press releases or legal disclosures made in their filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our update about the Company, we may from time to time include our own opinions about the Company, its business, markets, and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, sector or industry snapshot, podcast interview, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. A Speculative Buy rating for our covered companies is defined as a company that we believe exhibits the potential to generate outsized returns despite inherent, above-average business, market, or financial risk. To download this research report, or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research (GSCR) was compensated $5000 by a third party for the production and distribution of this report.

Contact:

Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com

SOURCE: Goldman Small Cap Research

View source version on accesswire.com:
https://www.accesswire.com/789910/goldman-small-cap-research-publishes-new-research-report-on-regen-biopharma-inc